INTENSITY THERAPEUTICS, INC. (INTS) Insider Trading & SEC Filings
Last SEC filing
INTENSITY THERAPEUTICS, INC. (INTS) has filed 9 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-20. 2 Form 8-K material event filings were reported by INTS in the last 90 days. InsiderAlpha tracks every INTS SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About INTENSITY THERAPEUTICS, INC. (INTS)
INTENSITY THERAPEUTICS, INC. trades under the ticker INTS. InsiderAlpha tracks 17 primary SEC Form 4 filings from 7 reporting insiders for INTS since 2024, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| SEC CIK | 0001567264 |
90-Day SEC Filing Activity
| Form 4 filings (90d) | 9 |
|---|---|
| Form 8-K filings (90d) | 2 |
| Latest Form 4 filing | 2026-07-20 |
Recent INTS Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| John M. Wesolowski | Principal Accounting Officer | A - Grant or award | 3.7K | $3.48 | $13K | SEC | |
| Joseph Talamo | Chief Financial Officer | A - Grant or award | 1.1K | $3.48 | $4K | SEC | |
| Lewis H. Bender | President and CEO | A - Grant or award | 37.7K | $6.11 | $231K | SEC | |
| Joseph Talamo | Chief Financial Officer | A - Grant or award | 14.2K | $0.26 | $4K | SEC | |
| John M. Wesolowski | Principal Accounting Officer | A - Grant or award | 69.7K | $0.26 | $18K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for INTENSITY THERAPEUTICS, INC. (INTS). Updated in real time as new filings are submitted to the SEC.
Most-Active INTS Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Joseph Talamo | 2 | $4K |
| John M. Wesolowski | 2 | $13K |
| Thomas I. H. Dubin | 1 | - |
| Lewis H. Bender | 1 | - |
| Mark A. Goldberg | 1 | - |
Recent INTS Form 8-K Material Events
- - Item 5.07 [SEC]
- - Item 2.02, 9.01 [SEC]
- - Item 2.02, 9.01 · Earnings · neutral [SEC]
Intensity Therapeutics released its financial results for the year ended December 31, 2025 on March 27, 2026. The filing provides standard annual financial results without explicit beat/miss or guidance language. - - Item 8.01, 9.01 · Financing · neutral [SEC]
Intensity Therapeutics increased the capacity of its existing at-the-market (ATM) offering program from an unspecified prior amount to $60.0 million. The company is under no obligation to issue shares and will only utilize the expanded facility at its discretion based on market c - - Item 8.01, 9.01 · Regulatory · positive [SEC]
Intensity Therapeutics regained compliance with Nasdaq's Minimum Bid Price Requirement by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days (February 19 - March 4, 2026). The company had previously received a deficiency notice in June 20
Recent Insider Filings
- - Thomas I. H. Dubin (Director)
- - Daniel Donovan (Director)
- - Mark A. Goldberg (Director)
- - Emer Leahy (Director)
- - John M. Wesolowski (Principal Accounting Officer)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in INTS insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
INTS Insider Trading - FAQ
- What is the latest insider trade for INTS?
- INTENSITY THERAPEUTICS, INC. (INTS) had 9 insider filings in the last 90 days, with the most recent on 2026-07-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying INTS stock?
- 0 insider purchases of INTS were filed in the last 90 days.
- How many insiders are selling INTS stock?
- 0 insider sales of INTS were filed in the last 90 days.
- Where can I see INTS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks INTS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $IVF INVO Fertility, Inc.
- $JAGX Jaguar Health, Inc.
- $JBIO Jade Biosciences, Inc.
- $JUNS JUPITER NEUROSCIENCES, INC.
- $KMTS KESTRA MEDICAL TECHNOLOGIES, LTD.
- $KOD Kodiak Sciences Inc.
- $KRRO Korro Bio, Inc.
- $KYMR Kymera Therapeutics, Inc.
- $LAB STANDARD BIOTOOLS INC.
- $LBRX LB PHARMACEUTICALS INC
Related Companies - Recent Insider Activity
- AMGEN INC (AMGN)
- NEUROCRINE BIOSCIENCES INC (NBIX)
- Twist Bioscience Corp (TWST)
- Kymera Therapeutics, Inc. (KYMR)
- EXELIXIS, INC. (EXEL)
- Moderna, Inc. (MRNA)
- RECURSION PHARMACEUTICALS, INC. (RXRX)
- BioCardia, Inc. (BCDA)
- Maze Therapeutics, Inc. (MAZE)
- MeiraGTx Holdings plc (MGTX)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live INTS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.